glp 1 vs glp2 Glucagon Like Peptide 2 Receptor - an overview Incretin-based therapies in MASLD/MASH: from

In addition, people with mental health conditions have an elevated risk of metabolic diseases such as obesity and type 2 diabetes

References 6B3J: Liang YL, Khoshouei M, Glukhova A, Furness SGB, Zhao P, Clydesdale L, Koole C, Truong TT, Thal DM, Lei S, Radjainia M, Danev R, Baumeister W, Wang MW, Miller LJ, Christopoulos A, Sexton PM, Wootten D

Some researchers, especially those with higher body weight or prior GLP-1 exposure, may not notice any appetite or metabolic changes at 2mg

PHEN/TPM ER, phentermine/topiramate extended release

If Im being curious, as I want to be, I need to be open to listening and learning and actually looking at data